Searched for
VIKRANT SHROTRIYA
Novo Nordisk price cuts set to shake up India’s GLP-1 market, challenge genericsNovo Nordisk is slashing prices for its diabetes and weight loss drugs Ozempic and Wegovy in India. This move aims to make these treatments...- Novo Nordisk cuts Ozempic and Wegovy prices by up to 48% as GLP-1 competition intensifies in IndiaNovo Nordisk has significantly slashed prices for Ozempic and Wegovy in India, reducing them by 36% and 48% respectively, to enhance patien...
- Novo to track generic surge as semaglutide goes off patentNovo Nordisk is preparing for a surge of generic semaglutide drugs in India. The company's India head stated they will monitor rivals' pric...
- Abbott signs pact with Novo Nordisk to offer semaglutideSemaglutide, sold by Novo Nordisk under brands such as Ozempic and Wegovy, goes off patent on March 21 in India. A raft of Indian generic d...
- Novo Nordisk bets on cheaper Ozempic to dominate India’s booming weight-loss marketNovo Nordisk has launched Ozempic in India at a competitive price, aiming to capture a significant share of the growing weight-loss market....
- Novo Nordisk gears up for December Ozempic launch in India, sources sayDanish drugmaker Novo Nordisk is set to launch its popular diabetes drug Ozempic in India this month. This move aims to capture a significa...
- Novo Nordisk India partners with Healthify to launch AI-enabled patient support programmeNovo Nordisk India and Healthify have launched a new programme. It offers AI-assisted lifestyle guidance for people with obesity. This part...
- Novo Nordisk India prioritises patient outcomes; revenue growth follows naturally, says ShrotriyaNovo Nordisk India head Vikrant Shrotriya revealed a strategic 37% price cut for obesity drug Wegovy, aiming for wider accessibility. The c...
- Patent expiry looms: Eli Lilly and Novo Nordisk strategise to defend their top obesity drugs in IndiaAt a recent industry summit, executives from Eli Lilly and Novo Nordisk unveiled their game plan for tackling weight-loss medications in In...
- Novo, Emcure to launch weight-loss drug under new brand in IndiaIn June, Novo Nordisk launched Wegovy (semaglutide) injections in five dosing strengths (0.25, 0.5, 1, 1.7 and 2.4 mg). However, the compan...
- Novo Nordisk ties up with Emcure to expand reach of weight-loss drug semaglutide in IndiaNovo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand n...
- IIM Ahmedabad, Novo Nordisk India partner to strengthen obesity care ecosystemThe Indian Institute of Management Ahmedabad (IIMA) and Novo Nordisk India have partnered to strengthen India's obesity care ecosystem. The...
- Novo Nordisk’s Wegovy enters India: Can this weight loss jab beat Mounjaro? Price, who can use it & how it worksNovo Nordisk has launched Wegovy, a weight loss injection, in India, challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy conta...
- Weight-loss drug Wegovy starts at ₹17,345 in IndiaNovo Nordisk launches Wegovy, a weekly weight-loss injectable, in India. The drug is available in five dosages, costing between Rs 17,345 a...
- Novo Nordisk launches blockbuster weight-loss drug Wegovy in India; Check price, dosage and other detailsNovo Nordisk has introduced its weight-loss drug, Wegovy, in India. This launch follows Eli Lilly's entry into the market. The company aims...
- Novo Nordisk aims for heavy sales in India with WegovyThe achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record for prescriptio...
- Novo Nordisk not yet ready to bring in popular obesity, diabetes injectablesNovo Nordisk's launch of weight-loss and diabetes drugs Wegovy and Ozempic in India hinges on resolving supply issues. The company is scali...
- Indiamart working with Novo Nordisk to halt illegal Wegovy salesThe drugmaker's India legal team held discussions with Indiamart's top executives to develop a "framework" for regularly alerting the onlin...
- Novo Nordisk India head eyes 2026 launch for obesity drug Wegovy, warns against copycatsNovo Nordisk plans to bring its weight-loss drug, Wegovy, to India in 2026. The company aims to secure regulatory approvals and ensure suff...
- Novo Nordisk launches anti-diabetes pill semaglutide in IndiaNovo Nordisk, the Danish drug maker on Thursday announced the launch of oral semaglutide in India for treatment of type 2 diabetes.
Load More
